SciVac Therapeutics Inc.
TSX : VAC
OTCQX : SVACF

SciVac Therapeutics Inc.

July 13, 2015 22:43 ET

SciVac Announces Listing on the Toronto Stock Exchange

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 13, 2015) - SciVac Therapeutics Inc. (the "Company", formerly Levon Resources Ltd.) (TSX:VAC)(OTCQX:SVACF) is pleased to announce that the Toronto Stock Exchange (the "TSX") has issued a bulletin confirming the listing of the Company's common shares (the "Common Shares") on the TSX under the symbol "VAC", commencing at the opening of the TSX on July 14, 2015. Also commencing at the opening of markets on July 14, 2015, the Common Shares will be quoted on the OTCQX under the symbol "SVACF".

The foregoing listing follows the completion of the previously announced reverse-takeover of the Company, pursuant to which the Company acquired 100% of the issued and outstanding securities of SciVac Ltd. ("SciVac") in exchange for 517,514,016 Common Shares (the "Transaction"). On completion of the Transaction, the Company changed its name from Levon Resources Ltd. to SciVac Therapeutics Inc. As a result of the Transaction, the Company will operate the business of SciVac.

For additional details concerning the Transaction, please see the Company's management information circular dated May 1, 2015 filed on the Company's profile on SEDAR at www.sedar.com (the "Circular").

About SciVac Therapeutics Inc.

SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. The Company's flagship product, Sci‐B‐Vac™, is a recombinant 3rd generation hepatitis B vaccine. The Company also has in-licensed an early-stage enzyme-based product designated S-Graft, which is a recombinant human deoxyribonuclease I, a repurposed biological therapeutic intended for the prevention and treatment of graft-versus-host disease (GVHD). The Company also offers contract development and manufacturing services to the life sciences and biotechnology markets.

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX), the Frankfurt Stock Exchange nor the OTCQX accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement on Forward-looking Information

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding the expected benefits of the Transaction and the operation of the Company's business are forward-looking statements that involve various risks and uncertainties.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's limited operating history and uncertainty surrounding future profitability; general economic and business conditions in Canada, Israel, and the other regions in which the Company operates; technological changes that could impact the Company's existing products or its ability to develop and commercialize future products; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; political, economic and military instability in Israel; and any other factors described in detail in the Circular. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the Company's current expectations and it undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Contact Information